Parkinson Disease
Conditions
Brief summary
The primary endpoint of the study is to identify a neurophysiological biomarker (absence of synaptic depotentiation at primary motor cortex , measured as change in the amplitude of motor evoked potentials recorded at the dorsal first interosseus muscle after administration of neurophysiological cTBS depotentiation protocol) as predictor of the development of Levodopa-induced dyskinesia in patients with Parkinson's disease.
Interventions
Two sessions of continuous theta burst stimulation over primary motor cortex to explore synaptic plasticity in Patients with Parkinson's disease
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* patients with diagnosis of idiopathic Parkinson's disease according to Movement Disorder Society (MDS) criteria; * age between 30 and 80 years; * ongoing therapy with levodopa; * fulfillment of requirements for the application of transcranial magnetic stimulation (TMS), assessed by completion of the TMS screening questionnaire.
Exclusion criteria
* patients unable to give informed consent; * cognitive impairment (MMSE ≤ 24); * history of epilepsy; * pregnant women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Alterations of synaptic depotentiation in primary motor cortex | 3 years | Alterations of synaptic depotentiation in primary motor cortex will be measured as change in the amplitude of motor evoked potentials recorded at the dorsal first interosseus muscle after administration of depotentiation protocol of continuous theta burst stimulation. Alterations of synaptic depotentiation at the baseline evaluation will be compared between patients who will develop and patients who will not develop dyskinesias (assessed by Unified Dyskinesia Rating Scale part III, range 0-112) during the follow-up. |
Countries
Italy
Contacts
Primary ContactFrancesco Bove, MD
Outcome results
None listed